CTOs on the Move

Allucent

www.allucent.com

 
Allucent is a global biopharmaceutical services company founded in 2022 through the merger of several specialized providers. The company focuses on supporting small and mid-sized biotech firms in developing innovative treatments for patients with unmet medical needs. With over 30 years of combined experience, Allucent offers a range of services including regulatory consulting, clinical operations management, biometrics, and clinical pharmacology, particularly emphasizing oncology. Headquartered in Cary, North Carolina, Allucent has a strong global presence with offices in North America, Europe, Central/Eastern Europe, and Asia/Middle East. The company has conducted more than 825 clinical trials across over 70 countries, showcasing its extensive ...
  • Number of Employees: 1K-5K
  • Annual Revenue: $50-100 Million

Executives

Name Title Contact Details
Mike Lynch
 Executive Director, IT Delivery Profile
Matt Edwards
 Sr. Director, IT Operations & Security Profile

Similar Companies

BC Biomedical Laboratories

BC Biomedical Laboratories Ltd. is a Surrey, BC-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

Lybradyn Inc

Lybradyn Inc is a Oak Brook, IL-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

FIRSTMED HOLDING CORP

FIRSTMED HOLDING CORP is one of the leading companies in the Healthcare, Pharmaceuticals, and Biotech sector.

Bioamerica

Bioamerica is a Homestead, FL-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

Eyenovia

Eyenovia is a clinical stage, biopharmaceutical company transforming the delivery of therapeutics for the treatment of prominent eye diseases, such as glaucoma, dry eyes, allergic eye disease and many others. Eyenovia`s breakthrough piezo-dispersion and microdosing technology enable a portfolio of first-in-class, next-generation, micro-therapeutics for the eye designed to reduce ocular and systemic toxicity and improve the risk-benefit profile of both new and existing therapeutics.